Regenxbio completes dosing in RGX-202 Duchenne confirmatory study ahead of planned Q3 2026 BLA filing

REGENXBIO, Inc.

REGENXBIO, Inc.

RGNX

0.00
  • Regenxbio completed dosing in the confirmatory study for RGX-202 in Duchenne muscular dystrophy, finishing the registrational development program ahead of schedule.
  • Topline pivotal results were already presented, showing the therapy met its main study goal and supported functional improvement signals.
  • The planned BLA filing remains on track for Q3 2026 under an accelerated approval pathway, targeting a potential FDA decision in 2H 2027.
  • The submission is set to rely on a broad safety package across pivotal and confirmatory studies, supported by efficacy evidence from the pivotal cohort.
  • Manufacturing for potential commercial supply has already started as the company prepares for a possible launch.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regenxbio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606240705PR_NEWS_USPR_____PH91042) on June 24, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.